Source comparison
Ipamorelin Peptide: Full Comparison
Receptor Selectivity GHS-R1a only GHS-R1a + ACTH GHS-R1a + ACTH + appetite GHS-R1a + cardiac receptors GHS-R1a (non-peptide) Ipamorelin's D-amino acid modifications eliminate off-target binding that confounds earlier GHRPs. No cortisol or prolactin elevation G
This comparison does not assign a generated winner or score.
- Receptor Selectivity
- GHS-R1a only
- GHS-R1a + ACTH
- GHS-R1a + ACTH + appetite
- GHS-R1a + cardiac receptors
- GHS-R1a (non-peptide)
- Ipamorelin's D-amino acid modifications eliminate off-target binding that confounds earlier GHRPs. No cortisol or prolactin elevation
- GH Release Magnitude
- 13–15× baseline
- 15–18× baseline
- 12–14× baseline
- 18–22× baseline
- 2–3× sustained
- Hexarelin produces the highest acute spike but with cardiac hypertrophy risk; Ipamorelin balances efficacy with clean selectivity
- Cortisol Elevation
- None detected
- Moderate (+40%)
- Moderate (+35%)
- Significant (+60%)
- Minimal
- Only Ipamorelin and MK-677 avoid cortisol activation. Critical for metabolic research where cortisol confounds insulin sensitivity and lipolysis
- Prolactin Elevation
- Mild (+20%)
- Mild (+25%)
- Moderate (+45%)
- None
- Prolactin interference with reproductive hormones and metabolic endpoints makes Ipamorelin the cleanest choice for endocrine research
- Half-Life
- ~2 hours (pulsatile)
- ~1.5 hours
- ~1 hour
- >24 hours (sustained)
- Ipamorelin's 2-hour half-life allows precise temporal control. Dose at Hour 0, measure GH at Hour 1, return to baseline by Hour 4
- Appetite Stimulation
- Moderate
- Strong (ghrelin-like)
- Mild
- Strong (persistent)
- GHRP-6 and MK-677 stimulate hunger through prolonged ghrelin receptor activation. Ipamorelin's transient binding avoids this confound in feeding studies